How many drugs treat Systemic AL amyloidosis?

Drug Landscape tracks 8 marketed treatments for Systemic AL amyloidosis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/systemic-al-amyloidosis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Systemic AL amyloidosis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Systemic AL amyloidosis (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Systemic AL amyloidosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Darzalex	daratumumab	Johnson & Johnson	Monoclonal antibody	CD38	2015-01-01
Velcade	bortezomib	Shilpa	Proteasome inhibitor	26S proteasome chymotrypsin-like activity	2003-01-01
Cytoxan (Lyophilized)	cyclophosphamide	Baxter	Alkylating agent	Tumor cell DNA	1959-01-01
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30
Wydase	HYALURONIDASE	Baxter	Endoglycosidase	hyaluronic acid	1950-01-01
Velcade	Velcade	University of Arkansas		26S proteasome non-ATPase regulatory subunit 1, PH and SEC7 domain-containing protein 1, Cathepsin G
Cyclophosphamid	Cyclophosphamid	Zhejiang University		Cytochrome P450 3A4
Darzalex	Darzalex	Shanghai Henlius Biotech		Lymphocyte differentiation antigen CD38

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Baxter · 3 drugs in Systemic AL amyloidosis
Generic (originally Merck) · 1 drug in Systemic AL amyloidosis
Johnson & Johnson · 1 drug in Systemic AL amyloidosis
Shanghai Henlius Biotech · 1 drug in Systemic AL amyloidosis
Shilpa · 1 drug in Systemic AL amyloidosis
University of Arkansas · 1 drug in Systemic AL amyloidosis
Zhejiang University · 1 drug in Systemic AL amyloidosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Systemic AL amyloidosis:

Cite this brief

Drug Landscape (2026). Systemic AL amyloidosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/systemic-al-amyloidosis. Accessed 2026-06-10.

Systemic AL amyloidosis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing